WO2007059311A3 - Furoxan compounds, compositions and methods of use - Google Patents

Furoxan compounds, compositions and methods of use Download PDF

Info

Publication number
WO2007059311A3
WO2007059311A3 PCT/US2006/044680 US2006044680W WO2007059311A3 WO 2007059311 A3 WO2007059311 A3 WO 2007059311A3 US 2006044680 W US2006044680 W US 2006044680W WO 2007059311 A3 WO2007059311 A3 WO 2007059311A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
compositions
diseases
compounds
endothelial dysfunctions
Prior art date
Application number
PCT/US2006/044680
Other languages
French (fr)
Other versions
WO2007059311A2 (en
Inventor
David S Garvey
Ramani R Ranatunge
Original Assignee
Nitromed Inc
David S Garvey
Ramani R Ranatunge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc, David S Garvey, Ramani R Ranatunge filed Critical Nitromed Inc
Priority to EP06837911A priority Critical patent/EP1954685A4/en
Priority to US12/093,561 priority patent/US7838023B2/en
Publication of WO2007059311A2 publication Critical patent/WO2007059311A2/en
Publication of WO2007059311A3 publication Critical patent/WO2007059311A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The inventio also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.
PCT/US2006/044680 2005-11-16 2006-11-16 Furoxan compounds, compositions and methods of use WO2007059311A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06837911A EP1954685A4 (en) 2005-11-16 2006-11-16 Furoxan compounds, compositions and methods of use
US12/093,561 US7838023B2 (en) 2005-11-16 2006-11-16 Furoxan compounds, compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73687105P 2005-11-16 2005-11-16
US60/736,871 2005-11-16

Publications (2)

Publication Number Publication Date
WO2007059311A2 WO2007059311A2 (en) 2007-05-24
WO2007059311A3 true WO2007059311A3 (en) 2007-12-21

Family

ID=38049315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044680 WO2007059311A2 (en) 2005-11-16 2006-11-16 Furoxan compounds, compositions and methods of use

Country Status (3)

Country Link
US (1) US7838023B2 (en)
EP (1) EP1954685A4 (en)
WO (1) WO2007059311A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8838195B2 (en) 2007-02-06 2014-09-16 Medtronic Minimed, Inc. Optical systems and methods for ratiometric measurement of blood glucose concentration
US8979790B2 (en) 2007-11-21 2015-03-17 Medtronic Minimed, Inc. Use of an equilibrium sensor to monitor glucose concentration
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921365B1 (en) * 2007-09-21 2012-10-12 Servier Lab NOVEL ADDITIONAL SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS TO NO DONOR ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
JP2013519101A (en) * 2010-02-08 2013-05-23 グルメトリクス， インコーポレイテッド Antioxidant protection of chemical sensors
RU2502739C9 (en) * 2012-10-31 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвити Thrombocyte aggregation-inhibiting n-carb(glutaminyl)oxymethylimidazo[4,5-e]benzo[1,2-c;3,4-c']difuroxane
JP5799062B2 (en) * 2013-08-23 2015-10-21 富山化学工業株式会社 Granular solid formulation containing tosufloxacin
RU2549355C1 (en) * 2014-02-17 2015-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) THROMBOCYTE AGGREGATION-INHIBITING N-CARB(ARGINYL)OXYMETHYLIMIDAZO[4,5-e]BENZO[1,2-c;3,4-c']DIFUROXANE
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
US10590119B2 (en) 2016-11-15 2020-03-17 The University Of Toledo Furoxans as therapies for neurodegenerative disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416893A (en) * 1980-04-02 1983-11-22 Cassella Aktiengesellschaft Substituted 1,2,5-oxadiazole-2-oxides in human cardiovascular system disease
US5389655A (en) * 1992-05-29 1995-02-14 Cassella Ag Phenylfuroxans
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780401A (en) * 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) * 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) * 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) * 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) * 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) * 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) * 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) * 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) * 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US5428061A (en) * 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
DE3841520A1 (en) * 1988-12-09 1990-06-13 Hoechst Ag ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE
US5106835A (en) * 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
DE4004820A1 (en) * 1989-08-05 1991-04-25 Bayer Ag RENININHIBITORS, METHOD FOR THE PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) * 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) * 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) * 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5071451A (en) * 1990-12-28 1991-12-10 Membrane Technology & Research, Inc. Membrane process and apparatus for removing vapors from gas streams
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5705583A (en) * 1991-07-05 1998-01-06 Biocompatibles Limited Polymeric surface coatings
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
DE4218977A1 (en) 1992-06-10 1993-12-16 Cassella Ag Annellated 1,2,5-oxadiazole-2-oxides
DE4223800A1 (en) 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Use of 1.2.5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB9216617D0 (en) 1992-08-05 1992-09-16 Donisthorpe & Company Limited Cylinders for storing thread
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5650447A (en) * 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
EP0680385B1 (en) 1993-01-13 1999-09-15 Derrick Manufacturing Corporation Undulating screen for vibratory screening machine and method of fabrication thereof
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
WO1994026731A1 (en) 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
DE4321306A1 (en) * 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh disulfide
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6087479A (en) * 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
ES2172959T3 (en) 1993-11-30 2002-10-01 Searle & Co PIRAZOLIL-BENCENOSULFONAMIDAS TRICICLICAS, REPLACED AND ITS USE AS INHIBITORS OF CYCLOOXYGENASE II.
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
DE4417705A1 (en) 1994-05-20 1995-11-23 Cassella Ag Substituted furoxanes
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5665077A (en) * 1995-04-24 1997-09-09 Nitrosci Pharmaceuticals Llc Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
NZ311304A (en) * 1995-06-07 1999-03-29 Cygnus Therapeutic Systems Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
TR199800767T2 (en) * 1995-10-30 1998-07-21 Smithkline Beecham Corporation Protease inhibitors.
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
TW394917B (en) * 1996-04-05 2000-06-21 Matsushita Electric Ind Co Ltd Driving method of liquid crystal display unit, driving IC and driving circuit
NZ331542A (en) * 1996-04-12 1999-07-29 Searle & Co Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors and salts thereof that are useful in treating inflammation and inflammation-related disorders
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
JP4856295B2 (en) * 1997-07-03 2012-01-18 アメリカ合衆国政府 Novel nitric oxide releasing amidine-derived diazeniumdiolate and its composition
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
CA2348741C (en) * 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
AU2004305016A1 (en) * 2003-12-10 2005-07-07 Nitromed, Inc. Nitric oxide releasing pyruvate compounds, compositions and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416893A (en) * 1980-04-02 1983-11-22 Cassella Aktiengesellschaft Substituted 1,2,5-oxadiazole-2-oxides in human cardiovascular system disease
US5389655A (en) * 1992-05-29 1995-02-14 Cassella Ag Phenylfuroxans
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8838195B2 (en) 2007-02-06 2014-09-16 Medtronic Minimed, Inc. Optical systems and methods for ratiometric measurement of blood glucose concentration
US8979790B2 (en) 2007-11-21 2015-03-17 Medtronic Minimed, Inc. Use of an equilibrium sensor to monitor glucose concentration
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same

Also Published As

Publication number Publication date
US7838023B2 (en) 2010-11-23
EP1954685A4 (en) 2009-11-11
WO2007059311A2 (en) 2007-05-24
US20080268014A1 (en) 2008-10-30
EP1954685A2 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
WO2007059311A3 (en) Furoxan compounds, compositions and methods of use
WO2004060283A3 (en) Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
WO2003086282A3 (en) Nitric oxide donors, compositions and methods of use
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008095841A3 (en) Nitric oxide donor compounds
WO2009063202A3 (en) Use of crth2 antagonist compounds
EP2090334A3 (en) Imidazole based compounds, compositions comprising them and methods of their use
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
EA201300583A1 (en) VASOPROTECTIVE AND CARDIOPROTECTIVE ANTI-DIABETIC TREATMENT
WO2012092471A3 (en) Novel tubulin inhibitors and methods of using the same
WO2006127591A3 (en) Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2009036082A3 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
BRPI0610644B8 (en) compound and pharmaceutical composition comprising such compound and a pharmaceutically acceptable carrier or diluent.
WO2009069032A3 (en) Novel glucocorticoid receptor agonists
WO2010034838A3 (en) Antiproliferative compounds
WO2005090333A8 (en) 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2009106980A3 (en) Indazole derivatives
WO2009061453A8 (en) Solubilized thiazolopyridines
EA201100255A1 (en) 5-Alkinylpyrimidines
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
BRPI0819505A2 (en) "compound, pharmaceutical composition, method for inhibiting abnormal cell growth and method for treating an inflammatory disease"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12093561

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006837911

Country of ref document: EP